HCPLive Network

Osteoporosis Therapy Has Unclear Impact on Spinal Fusion

FRIDAY, March 1 (HealthDay News) -- The effect of osteoporosis therapies (bisphosphonate drugs and intermittent parathyroid hormone [PTH]) on spinal fusion is unclear, according to a review published in the February issue of The Spine Journal.

Brandon P. Hirsch, MD, of the University of Miami/Jackson Health System, and colleagues conducted a systematic review of the literature from 1980 to 2011 to assess the potential impact of bisphosphonates and PTH on fusion rate and quality in spinal arthrodesis. Eighteen animal studies and one clinical trial were included in the review.

The researchers found that most animal studies showed that bisphosphonates have no significant impact on fusion rate but that treatment may result in less histologically mature fusion mass; the impact of these changes on fusion mass biomechanics was unclear. Based on the human study, bisphosphonates had no impact on clinical outcome but may have increased the radiographically defined fusion rate. PTH improved the fusion rate and fusion mass microstructure in animals, but data were lacking for the effect on fusion mass biomechanics. There were no studies that assessed the impact of PTH on spine mass in humans.

"In the absence of conclusive human data relating to spine fusion, we recommend the continuation or initiation of these therapies in patients based on their indication for the treatment of osteoporosis, without regard for a recent or impending spine fusion procedure," the authors write. "However, on the basis of preclinical data, we believe that anabolic agents may offer an advantage over antiresorptive medications in osteoporotic patients undergoing spine fusion."

One author disclosed financial ties to the biopharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
The Relative Value Unit is a useful tool for managing practice finances, according to an article published Feb. 25 in Medical Economics.
For patients with moderate-to-severe rheumatoid arthritis (RA), continued etanercept treatment is associated with reduced work and activity impairment.
Patients who discuss weight loss with their physicians but do not feel judged may be more likely to attempt and succeed in losing weight, according to research published online Feb. 9 in Preventive Medicine.
Value-based insurance design plans with certain features aside from solely lowering cost sharing can increase medication adherence, according to a study published in the March issue of Health Affairs.
From 2012 to 2013, there was a 5.7 percent increase in the median total cash compensation for primary care physicians, with a smaller gap seen for medical and surgical specialists, according to the results of a recent survey from SullivanCotter.
Gender differences exist in domestic activities among career-oriented academic physicians with children, according to a study published online March 3 in the Annals of Internal Medicine.
Medical schools are beginning to change their curriculum to address ways to eliminate health disparities, according to the American Medical Association.
More Reading